2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Hyperplasia
1
Interventions
Dutasteride
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
Transurethral Resection of Prostate
2
Therapeutics
2
Radiotherapy
2
Prostatectomy
2
Blood Specimen Collection
2
proxalutamide
1
polyphenon E
1
mirabegron
1
Urination
1
TroVax
1
Transurethral Resection of Bladder
1
Tamsulosin
1
Standard of Care
1
Risedronic Acid
1
Psychiatric Rehabilitation
1
Prostate-Specific Antigen
1
Papaverine
1
Oxygen
1
Nitrous Oxide
1
Needles
1
Microspheres
1
Magnetic Resonance Spectroscopy
1
Lycopene
1
Levofloxacin
1
Finasteride
1
Electroacupuncture
1
Doxazosin
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Hyperplasia
×
5-alpha Reductase Inhibitors
×
Clear all
NCT01767363
2016-11-09
WEUSKOP5723: Prostate Cancer Study
GlaxoSmithKline
Completed
1 enrolled